natgillin/translations-raw huggingface dataset:
In vitro inducerede vareniclin desuden ikke aktiviteten af CYP450-enzymerne 1A2 og 3A4 i humane hepatocytter. 
Also, in human hepatocytes in vitro, varenicline was shown to not induce the activity of cytochrome P450 enzymes 1A2 and 3A4.
Dette studie viste den gavnlige virkning af yderligere 12 ugers behandling med CHAMPIX 1 mg 2 gange dagligt for at fastholde rygeophør sammenlignet med placebo. 
This study showed the benefit of an additional 12-week treatment with CHAMPIX 1 mg twice daily for the maintenance of smoking cessation compared to placebo; superiority to placebo for CA was maintained through week 52.
Nedsat antal blodplader Metabolisme og ernæring Almindelig 
Platelet count decreased Metabolism and nutrition disorders Common
I denne gruppe er seponeringsraten for de hyppigste bivirkninger hos patienter, der blev behandlet med vareniclin: kvalme (2,7% versus 0,6% for placebo), hovedpine (0,6% versus 1,0% for placebo), søvnløshed (1,3% versus 1,2% for placebo) og unormale drømme (0,2% versus 0,2% for placebo). 
In this group, the discontinuation rates for the most common adverse reactions in varenicline treated patients were as follows: nausea (2.7% vs. 0.6% for placebo), headache (0.6% vs. 1.0% for placebo), insomnia (1.3% vs. 1.2% for placebo), and abnormal dreams (0.2% vs. 0.2% for placebo).
Procentdelen af patienter med selvmordsrelaterede hændelser i den aktive behandlingsfase sammenlignet med fasen efter behandling var uændret i vareniclin-gruppen. 
The percentage of subjects with suicide-related events in the active treatment phase compared to post-treatment phase was unchanged in the varenicline group; in the placebo group, this percentage was lower in the post-treatment phase.
Forhøjet blodtryk, hedestigninger Luftveje, thorax og mediastinum Almindelig 
Blood pressure increased, hot flush Respiratory, thoracic and mediastinal disorders Common
Oddsratio (95% CI), p-værdi 
Odds ratio (95% CI), p value
4-ugers startpakning 
4-week treatment initiation pack
Erytem, akne, hyperhidrose, nattesved 
Rash, pruritus Erythema, acne, hyperhidrosis, night sweats
Må ikke opbevares ved temperaturer over 30 °C. 
Store below 30°C
CO-bekræftet afholdenhed i løbet af uge 9 til og med 12 og 9 til og med 24 sammenlignet med forsøgspersoner, der blev behandlet med bupropion, nikotinplaster og placebo (se nedenstående tabel). 
In both cohorts, subjects treated with varenicline demonstrated statistical superiority of CO-confirmed abstinence during weeks 9 through 12 and 9 through 24 compared to subjects treated with bupropion, nicotine patch and placebo (please see table below).
Risikoen for at begynde at ryge igen efter behandling er højest i perioden umiddelbart efter, at behandlingen er slut. 
In smoking cessation therapy, risk of returning to smoking may be elevated in the period immediately following the end of treatment.
Højdosis-vareniclin Lavdosis-vareniclin Placebo 
High-Dose Varenicline Low-Dose Varenicline Placebo
Tal med lægen, før De starter behandlingen med CHAMPIX, hvis De har haft krampeanfald eller har epilepsi. 
Tell your doctor if you have experienced seizures or have epilepsy before your start CHAMPIX treatment.
Patienter, der med succes er stoppet med at ryge efter 12 uger, kan overveje at tage yderligere en kur på 12 uger med CHAMPIX 1 mg 2 gange dagligt for at fastholde afholdenheden (se pkt. 
For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHAMPIX at 1 mg twice daily may be considered for the maintenance of abstinence (see section 5.1).
Filmovertrukkne tabletter 
Film-coated tablets
Prækliniske data afslørede ingen risiko hos mennesker baseret på standard-fertilitetsstudier hos hanog hunrotter (se pkt. 
Non-clinical data revealed no hazard for humans based on standard male and female fertility studies in the rat (see section 5.3).
Vedvarende afholdenhedsrate for forsøgspersoner, der fik CHAMPIX, sammenlignet med placebo 
Continuous Abstinence Rates in Subjects Treated with Champix versus Placebo
Det primære endepunkt var en CO-bekræftet 4W-CQR fra uge 9 til og med uge 12 og et sekundært endepunkt var CA fra uge 9 til og med uge 52. 
The primary endpoint of the study was the CO-confirmed, 4-week Continuous Quit Rate (4W CQR) from week 9 through week 12 and a key secondary endpoint was the Continuous Abstinence (CA) from Week 9 through Week 52.
Hos patienter med nyresygdom i sidste stadie blev vareniclin effektivt fjernet ved dialyse (se pkt. 
In subjects with end-stage-renal disease (ESRD), varenicline was efficiently removed by haemodialysis (see section 4.2).
12 til 17 år n/N (%) 
12-to-17-Year Olds n/N (%)
Det primære endepunkt for de 2 studier, er den 4 ugers vedvarende kvit-rate (4-week Continuous Quit Rate, 4W-CQR) fra uge 9 til og med uge 12, som er bekræftet ved måling af carbonmonoxid (CO). 
The primary endpoint of the two studies was the carbon monoxide (CO) confirmed, 4-week continuous quit rate (4W-CQR) from week 9 through week 12.
De hyppigste bivirkninger i vareniclin-gruppen var kvalme (23,8% vs. 14,0% i placebo-gruppen), hovedpine (10,7% vs. 18,6% i placebo-gruppen) og opkastning (10,7% vs. 9,3% i placebo-gruppen). 
The most common adverse events in subjects taking varenicline were nausea (23.8% vs. 14.0% on placebo), headache (10.7% vs. 18.6% on placebo) and vomiting (10.7% vs. 9.3% on placebo).
Gastroøsofageal reflukssygdom, opkastning, forstoppelse, diarré, udspilet abdomen, abdominalsmerter, tandpine, dyspepsi, flatulens, mundtørhed 
Gastrooesophageal reflux disease, vomiting, constipation, diarrhoea, abdominal distension, abdominal pain, toothache, dyspepsia, flatulence, dry mouth
Under behandlingen Antal vurderet Suicidaladfærd og/eller -tanker Suicidaladfærd Suicidaltanker Under opfølgning Antal vurderet Suicidaladfærd og/eller -tanker Suicidaladfærd Suicidaltanker 
During treatment Number assessed Suicidal behaviour and/or ideation Suicidal behaviour Suicidal ideation During follow up Number assessed Suicidal behaviour and/or ideation Suicidal behaviour Suicidal ideation
Ikke-psykiatrisk kohorte N=3984 Vareniclin Bupropion Nikotinplaster Placebo 
Non-psychiatric Cohort N=3984 Varenicline Bupropion
Vareniclin (n=5.072) 
Varenicline (N=5072)
Dag 8-14 Fra dag 8-14 skal De tage 1 lyseblå CHAMPIX 1 mg filmovertrukken tablet 2 gange dagligt, 1 om morgenen og 1 om aftenen på omtrent samme tidspunkt hver dag 
Day 8 - 14 From day 8 to day 14, you should take one light blue CHAMPIX 1 mg film-coated tablet twice daily, once in the morning and once in the evening, at about the same time each day.
Efter enkeltdosis og efter multiple doser til pædiatriske patienter i alderen 12-17 år (begge inklusive) var vareniclins farmakokinetik stort set dosis-proportional i det undersøgte dosisinterval på 0,5-2 mg dagligt. 
Single and multiple-dose pharmacokinetics of varenicline have been investigated in paediatric patients aged 12 to 17 years old (inclusive) and were approximately dose-proportional over the 0.5 mg to 2 mg daily dose range studied.
Nogle personer har oplevet krampeanfald, mens de var i behandling med CHAMPIX. 
Some people have reported seizures while taking CHAMPIX.
Nedsat leverfunktion Dosisjustering er ikke nødvendig hos patienter med nedsat leverfunktion (se pkt. 
Hepatic impairment No dosage adjustment is necessary for patients with hepatic impairment (see section 5.2).
Psykiatrisk kohorte N=4074 Vareniclin Bupropion Nikotinplaster Placebo 
Psychiatric Cohort N=4074 Varenicline Bupropion
CA = vedvarende afholdenhedsrate (continuous abstinence rate), CI = konfidensinterval, NRT = nikotinplaster (nicotine replacement therapy patch) 
CA = continuous abstinence rate; CI = confidence interval; NRT=Nicotine replacement therapy patch
Vareniclin ændrer ikke farmakokinetikken for warfarin. 
Varenicline did not alter the pharmacokinetics of warfarin.
Hos unge med legemsvægt ≤55 kg blev der efter indgift af 0,5 mg 2 gange dagligt set et vareniclin-niveau ved steadystate, der gennemsnitligt var højere (ca. 40%) sammenlignet med voksne. 
When 0.5 mg twice daily was given, steady-state daily exposure of varenicline was, on average, higher (by approximately 40%) in adolescent patients with bodyweight ≤ 55 kg compared to that noted in the adult population.
Antal behandlede patienter Sammensat primært endepunkt for NPS AE n (%) 
Number of Patients Treated 990 Composite NPS AE Primary Endpoint, n (%)
Filmovertrukne tabletter 11 x 0,5 mg og 14 x 1 mg 
11 x 0.5 mg and 14 x 1 mg
Patienterne blev randomiseret til CHAMPIX 1 mg 2 gange dagligt (n=353) eller placebo (n=350) i 12 uger og blev derefter fulgt i 40 uger efter behandling. 
Subjects were randomised to CHAMPIX 1 mg twice daily (n=353) or placebo (n=350) for 12 weeks and then were followed for 40 weeks post-treatment.
Fastholdelse af afholdenhed 
Treatment discontinuation
Fra dag 15 og til behandlingen er slut, skal De tage 1 lyseblå CHAMPIX 1 mg filmovertrukken tablet 2 gange dagligt, 1 om morgenen og 1 om aftenen på omtrent samme tidspunkt hver dag 
From day 15 until the end of treatment, you should take one light blue CHAMPIX 1 mg film-coated tablet twice daily, once in the morning and once in the evening, at about the same time each day.
Hvis De glemmer at tage en dosis, bør De tage den straks, De kommer i tanke om det, medmindre der kun er 3-4 timer til at næste dosis skal tages. 
If you forget to take a dose, take it as soon as you remember.
Patienter med stabil skizofreni eller skizoaffektiv sindslidelse Vareniclins sikkerhed og tolerabilitet blev undersøgt i et dobbelt-blindet studie med 128 rygere med stabil skizofreni eller skizoaffektiv sindslidelse, der fik antipsykotika. 
Study in subjects with stable schizophrenia or schizoaffective disorder Varenicline safety and tolerability was assessed in a double-blind study of 128 smokers with stable schizophrenia or schizoaffective disorder, on antipsychotic medication, randomised 2:1 to varenicline (1 mg twice daily) or placebo for 12 weeks with 12-week non-drug follow-up.
Kliniske forsøg har vist, at det vil forøge Deres chancer for at holde op med at ryge, hvis alle doser tages på de fastsatte tidspunkter og i den periode, som bliver foreslået. 
It has been shown in clinical trials that taking all doses of your medicine at the appropriate times and for the recommended duration of treatment described above will increase your chances of stopping smoking.
Sammenlignet med placebo har CHAMPIX desuden en signifikant reducerende effekt på de forstærkende virkninger af rygningen, der kan føre til, at de patienter, der ryger under behandlingen, ikke kan komme af med deres rygevaner. 
CHAMPIX also significantly reduced reinforcing effects of smoking that can perpetuate smoking behaviour in patients who smoke during treatment compared with placebo.
4W-CQR for vareniclin og placebo var hhv. 47,3% og 14,3% og CA uge 9-52 var 19,8% (vareniclin) vs. 7,4% (placebo). 
The 4 week CQR for varenicline and placebo was 47.3% and 14.3%, respectively and the CA week 9-52 was 19.8% (varenicline) vs. 7.4% (placebo).
CHAMPIX er beregnet til at tage gennem munden. 
Champix is for oral use.
Eksempelvis er følgende symptomer set hos patienter, der prøvede på at holde op med at ryge: dysfori og nedtrykt sindstilstand; søvnløshed, irritabilitet, frustration eller vrede; angst; koncentrationsbesvær; rastløshed; nedsat hjerterytme; øget appetit eller vægtøgning. 
For example, dysphoric or depressed mood; insomnia, irritability, frustration or anger; anxiety; difficulty concentrating; restlessness; decreased heart rate; increased appetite or weight gain have been reported in patients attempting to stop smoking.
Fra dag 4-7 skal De tage 1 hvid CHAMPIX 0,5 mg filmovertrukken tablet 2 gange dagligt, 1 om morgenen og 1 om aftenen på omtrent samme tidspunkt hver dag 
From day 4 to day 7, you should take one white CHAMPIX 0.5 mg film-coated tablet twice daily, once in the morning and once in the evening, at about the same time each day.
Vareniclin påvirker ikke farmakokinetikken for metformin. 
Varenicline did not affect the pharmacokinetics of metformin.
Hvide, kapselformede, bikonvekse tabletter præget ”Pfizer” på den ene side og ”CHX 0.5” på den anden side. 
White, capsular-shaped, biconvex tablets debossed with “Pfizer” on one side and “CHX 0.5” on the other side.
Forsøgspersonerne blev randomiseret til at få enten CHAMPIX 1 mg to gange dagligt (n=760) eller placebo (n=750) i 24 uger og blev fulgt efter behandlingen til og med uge 52. 
Subjects were randomised to either CHAMPIX 1 mg twice daily (n=760) or placebo (n=750) for 24 weeks and followed up post-treatment through week 52.
I dette 24-ugers studie fik patienterne behandling i 12 uger efterfulgt af en 12-ugers opfølgningsfase uden behandling. 
In this 24-week study, patients received treatment for 12 weeks followed by a 12 week non-treatment follow up phase.
Sådan skal De tage CHAMPIX 
How to take CHAMPIX
hallucinationer, ændringer i seksuel aktivitet - Krampeanfald, rysten, træthedsfornemmelse, nedsat følesans - Konjunktivitis, øjensmerter - Ringen for ørene (tinnitus) - Brystsmerter, hurtige hjerteslag, hurtig puls, hjertebanken - Forhøjet blodtryk, hedestigninger - Betændelse i næse, bihuler eller hals, tilstoppet næse, hals eller bryst, hæshed, høfeber, 
hallucinations, changes in sex drive o Seizure, tremor, feeling sluggish, less sensitive to touch o Conjunctivitis, eye pain o Ringing in the ears o Angina, rapid heart rate, palpitations, increased heart rate o Increased blood pressure, hot flush o Inflammation of nose, sinuses and throat, congestion of nose, throat and chest,
bGrad = AE af moderat og svær intensitet, NRT = nikotinplaster (nicotine replacement therapy patch) 
AE, adverse event; aGrade = severe intensity AE; bGrade = moderate and severe intensity AE; NRT=Nicotine replacement therapy patch
Højdosis-vareniclin vs. placebo Lavdosis-vareniclin vs. placebo 
High-Dose Varenicline vs Placebo Low-Dose Varenicline vs Placebo
CA-raten mellem uge 9 og 12 var 35,9 % i vareniclin-armen sammenlignet med 15,6 % i placebo-armen (OR 3,35 (95 % CI 2,16-5,21)), og CA-raten mellem uge 9 og 52 hhv. 20,3 % og 10,4 % (OR 2,36 (95 % CI 1,40-3,98)). 
Continuous abstinence rate between weeks 9-12 was 35.9% in the varenicline treatment group versus 15.6% in the placebo group (OR 3.35 (95% CI 2.16-5.21)) and between weeks 9-52 was 20.3% versus 10.4% respectively (OR 2.36 (95% CI 1.40-3.98)).
Meget almindelig Hovedpine Almindelig 
Very common Nausea
Selvmordstanker, aggression, panikanfald, abnorm tankegang, rastløshed, humørsvingninger, depression*, angst*, hallucinationer*, øget libido, nedsat libido 
Suicidal ideation, aggression, panic reaction, thinking abnormal, restlessness, mood swings, depression*, anxiety*, hallucinations*, libido increased, libido decreased Psychosis, somnambulism, abnormal behaviour, dysphoria, bradyphrenia Nervous system disorders Very common Headache Common
Blod- og lymfesystem Sjælden 
Fungal infection, viral infection Blood and lymphatic system disorders Rare
Behandling med CHAMPIX af patienter med nyresygdom i sidste stadie kan ikke anbefales, på grund af utilstrækkelig klinisk erfaring med denne patientgruppe (se pkt. 
Based on insufficient clinical experience with CHAMPIX in patients with end stage renal disease, treatment is not recommended in this patient population (see section 5.2).
CA Uge 9-52 
CA Wk 9-52
Cerebrovaskulær hændelse, hypertoni, dysartri, koordinationsforstyrrelser, hypogeusi, forstyrrelse i den cirkadiske søvn-vågencyklus 
Cerebrovascular accident, hypertonia, dysarthria, coordination abnormal, hypogeusia, circadian rhythm sleep disorder Transient loss of consciousness
4W-CQR (uge 9-12) for vareniclin og placebo var hhv. 53,9% og 19,4% (difference = 34,5%; 95% CI: 27,0%-42,0%) og CA uge 9-24 var 35,2% (vareniclin) vs. 12,7% (placebo) (difference = 22,5%; 95% CI: 15,8%-29,1%). 
The 4 week (week 9-12) CQR for varenicline and placebo was 53.9% and 19.4%, respectively (difference=34.5%, 95% CI: 27.0%42.0%) and the CA week 9-24 was 35.2% (varenicline) vs. 12.7% (placebo) (difference=22.5%, 95% CI: 15.8% - 29.1%).
Angstlidelser og -symptomer 
Heart symptoms
Hos patienter med alvorligt nedsat nyrefunktion (anslået kreatininclearance <30 ml/min) er vareniclinniveauet øget 2,1 gange. 
In subjects with severe renal impairment (estimated creatinine clearance < 30 ml/min), varenicline exposure was increased 2.1-fold.
Forsøgspersoner, der blev behandlet med CHAMPIX, opnåede en væsentlig højere vedvarende afholdenhedsrate sammenlignet med dem placebogruppen. 
Subjects treated with CHAMPIX had a significantly higher Continuous Abstinence Rate compared with placebo; the key results are summarised in the following table:
Hvis De er i tvivl så spørg lægen eller apoteket. 
If you have any further questions, ask your doctor or pharmacist.
Neuropsykiatrisk sikkerhed - metaanalyser og observationsstudier Analyser af data fra kliniske studier viste ikke evidens for øget risiko for svære neuropsykiatriske hændelser med vareniclin sammenlignet med placebo. 
Analyses of clinical trial data did not show evidence of an increased risk of serious neuropsychiatric events with varenicline compared to placebo.
AE = bivirkning, NRT = Nikotinplaster (nicotine replacement therapy patch) 
AE, adverse event; NRT=Nicotine replacement therapy patch
Brugen af vareniclin hos patienter med eller uden tidligere psykisk forstyrrelse var ikke forbundet med en øget risiko for alvorlige, neuropsykiatriske bivirkninger i det sammensatte, primære endepunkt sammenlignet med placebo (se pkt. 
The use of varenicline in patients with or without a history of psychiatric disorder was not associated with an increased risk of serious neuropsychiatric adverse events in the composite primary endpoint compared with placebo (see section 5.1 Pharmacodynamic properties - Study in Subjects with and without a History of Psychiatric Disorder).
Der blev rapporteret flere hændelser for patienter i den psykiatriske kohorte i hver behandlingsgruppe sammenlignet med den ikke-psykiatriske kohorte. 
There were more events reported in patients in the psychiatric cohort in each treatment group compared with the non-psychiatric cohort, and the incidence of events in the composite endpoint was higher for each of the active treatments compared to placebo.
N=1006 n (%) 
NRT N=1006 n (%)
Indeholder: 11 x 0,5 mg filmovertrukne tabletter og 
11 x 0.5 mg film-coated tablets and
Sammensat endepunkt for NPS AE af svær grad, n (%) 
Composite NPS AE Endpoint of severe intensity n (%)
Nikotinplaster N=2022 
NRT N=2022
Effekten af at holde op med at ryge 
The effects of stopping smoking
0,5 mg filmovertrukne tabletter på 4 mm x 8 mm: Hvide, kapselformede, bikonvekse tabletter præget ”Pfizer” på den ene side og ”CHX 0.5” på den anden side. 
0.5 mg film-coated tablets of 4mm x 8mm: White, capsular-shaped, biconvex tablets debossed with “Pfizer” on one side and “CHX 0.5” on the other side.
Oddsratio (95% CI) 
Odds ratio (95% CI)
Inflammation i de øvre luftveje, tilstopning af luftveje, dysfoni, allergisk rhinitis, halsirritation, tilstoppede bihuler, øvre luftvejhoste-syndrom (upper-airway cough syndrom), næseflåd 
Upper respiratory tract inflammation, respiratory tract congestion, dysphonia, rhinitis allergic, throat irritation, sinus congestion, upperairway cough syndrome, rhinorrhoea Laryngeal pain, snoring
Kardiovaskulær sikkerhedsvurderingsstudie med forsøgspersoner med eller uden en psykiatrisk lidelse i anamnesen 
Neuropsychiatric Safety Study in Subjects with and without a History of Psychiatric Disorder:
Filmovertræk - CHAMPIX 1 mg filmovertrukne tabletter Hypromellose 
Tablet film coating - CHAMPIX 1 mg film-coated tablets Hypromellose
Forsøgspersonerne blev randomiseret 1:1 til behandling i 12 uger med CHAMPIX 1 mg to gange dagligt (n=249) eller placebo (n=245) og blev fulgt i op til 40 uger efter behandlingen. 
Subjects were randomised 1:1 to CHAMPIX 1 mg twice daily (N=249) or placebo (N=245) for 12 weeks of treatment and followed for up to 40 weeks post-treatment.
CHAMPIX indeholder: 
CHAMPIX is available in the following pack presentations:
Pfizer Europe MA EEIG (som logo for indehaver af markedsføringstilladelse) 
NAME OF THE MARKETING AUTHORISATION HOLDER Pfizer Europe MA EEIG (as MA Holder Logo)
Brystsmerter, træthed 
Chest pain, fatigue
Rygeophør kan give forskellige symptomer, hvad enten det gennemføres med eller uden behandling. 
Giving up smoking with or without treatment can cause various symptoms.
Det frarådes at anvende CHAMPIX hos pædiatriske patienter, eftersom der ikke er påvist virkning i denne population (se pkt. 
CHAMPIX is not recommended for use in paediatric patients because its efficacy in this population was not demonstrated (see sections 5.1 and 5.2).
Vedligeholdelsespakning indeholdende 56 filmovertrukne tabletter 
PHARMACEUTICAL FORM AND CONTENTS 56 Film-coated tablets
CHAMPIX og de nedenfor nævnte lægemidler, kan administreres samtidigt, uden det er nødvendigt at dosisjustere. 
No dosage adjustment of CHAMPIX or co-administered medicinal products listed below is recommended.
Filmovertræk - CHAMPIX 0,5 mg filmovertrukne tabletter Hypromellose 
Tablet film coating - CHAMPIX 0.5 mg film-coated tablets Hypromellose
Sammensat primært endepunkt for NPS AE, n 
Treated Composite NPS AE
Lyseblå, kapselformede, bikonvekse tabletter præget ”Pfizer” på den ene side og ”CHX 1.0” på den anden side. 
Light blue, capsular-shaped, biconvex tablets debossed with “Pfizer” on one side and “CHX 1.0” on the other side.
N=1016 n (%) 
NRT N=1016 n (%)
Vedligeholdelsespakning indeholdende 28 filmovertrukne tabletter 
28 film-coated tablets
Karton indeholdende 2 blisterkort hver med 14 x 1 mg vareniclin filmovertrukne tabletter eller 4 blisterkort hver med 14 x 1 mg vareniclin filmovertrukne tabletter eller 8 blisterkort hver med 14 x 1 mg vareniclin filmovertrukne tabletter eller 10 blisterkort hver med 14 x 1 mg vareniclin filmovertrukne tabletter 
Carton pack containing 2 blister packs of 14 x 1 mg varenicline film-coated tablets or 4 blister packs of 14 x 1 mg varenicline film-coated tablets or 8 blister packs of 14 x 1 mg varenicline film-coated tablets or 10 blister packs of 14 x 1 mg varenicline film-coated tablets
Vareniclin ændrer ikke farmakokinetikken for digoxin i steady state. 
Varenicline did not alter the steady-state pharmacokinetics of digoxin.
irriteret hals, tilstoppede bihuler, hoste forårsaget af øget slimdannelse i næsen, løbenæse - Rødt blod i afføringen, maveirritation, ændrede afføringsvaner, bøvsen, mundsår, smerter i gummerne - Hudrødmen, bumser, øget svedtendens, nattesved - Muskelspasmer, smerter i brystkassen - Unormal, hyppig vandladning, natlig vandladning - Kraftigere menstruation - Ubehag i brystet, influenzalignende symptomer, feber, svaghedsfølelse eller følelse af ubehag - Højt blodsukker - Hjerteanfald - Selvmordstanker - Ændret tankegang og adfærd (f.eks. aggressiv og unormal adfærd). 
pain in the gums o Reddening of the skin, acne, increased sweating, night sweats o Muscle spasms, chest wall pain o Abnormally frequent urination, urination at night o Increased menstrual flow o Chest discomfort, flu like illness, fever, feeling weak or unwell o High blood sugar o Heart attack o Suicidal thoughts o Changes in thinking or behaviour (such as aggression)
Rygeophør kan føre til ændringer i Deres krop, og det kan ændre virkningen af anden medicin. 
The effects of changes in your body resulting from stopping smoking, with or without treatment with CHAMPIX, may alter the way other medicines work.
Vareniclin ændrer ikke farmakokinetikken af bupropion i steady state. 
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Den anbefalede dosis af CHAMPIX hos patienter med svært nedsat nyrefunktion (anslået kreatininclearance <30 ml/min) er 1 mg 1 gang dagligt. 
For patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended dose of CHAMPIX is 1 mg once daily.
Er De i tvivl, så spørg lægen eller apotekspersonalet. 
If in doubt, you should consult your doctor or pharmacist.